Danaher's Masimo Gets FDA Clearance for Opioid-Induced Respiratory Depression Detection
Danaher (DHR) subsidiary Masimo received FDA 510(k) clearance for opioid-induced respiratory depression detection capability integrated into the Radius VSM wearable continuous patient monitor.
Masimo, the specialty diagnostics solutions innovator of Danaher Corporation (NYSE:DHR), announced on June 22 that it received FDA 510(k) clearance for an opioid-induced respiratory depression (OIRD) detection capability integrated into the Radius VSM® wearable continuous patient monitor.
The Product
The clearance enables the Radius VSM® to detect early signs of OIRD, a life-threatening condition that often occurs in hospitals when opioid painkillers are used. The device provides continuous, wire-free monitoring, allowing for early intervention.
Pricing and Availability
Masimo has not yet disclosed pricing or commercial availability details for the new capability.
Competition
Danaher faces competition from other patient monitoring companies such as Medtronic and GE Healthcare. However, the integrated OIRD detection in a wearable device could provide a competitive edge.
Potential Impact on the Company
The FDA clearance is expected to strengthen Danaher's position in the specialty diagnostics market, especially as patient safety in hospitals gains attention. It could contribute to future revenue growth in the diagnostics segment.
Frequently Asked Questions
Found this useful? Share it